Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News HLS Therapeutics Inc T.HLS

Alternate Symbol(s):  HLTRF

Healthcare Industrials Auto Parts Diversified Industrials
HLS Therapeutics Inc. is a pharmaceutical company. It is focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. It is also focused on products targeting the... see more

Recent & Breaking News (TSX:HLS)

HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Canada NewsWire 9 days ago

New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Canada NewsWire 10 days ago

HLS Therapeutics Announces Fiscal 2023 Financial Results

Canada NewsWire March 14, 2024

HLS Therapeutics to Host Q4 and Fiscal 2023 Financial Results Conference Call

Canada NewsWire February 29, 2024

HLS Announces that Vascepa® is now reimbursed by British Columbia's Provincial Drug Plan

Canada NewsWire February 6, 2024

HLS Therapeutics Announces CFO Departure

Canada NewsWire December 18, 2023

New REDUCE-IT® Analyses Show Vascepa® (Icosapent Ethyl) Associated with 29 Percent Relative Risk Reduction Compared with Placebo in Prespecified Subgroup of Patients with Metabolic Syndrome, but Without Diabetes at Baseline

Canada NewsWire November 14, 2023

HLS Therapeutics Announces Q3 Fiscal 2023 Financial Results and Renewal of Normal Course Issuer Bid

Canada NewsWire November 9, 2023

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

Canada NewsWire October 26, 2023

HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

Canada NewsWire September 6, 2023

HLS Therapeutics Announces Updates to its Credit Agreement

Canada NewsWire August 14, 2023

HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

Canada NewsWire August 10, 2023

HLS Therapeutics to Host Q2 Fiscal 2023 Financial Results Conference Call

Canada NewsWire August 3, 2023

HLS Therapeutics Announces Updates to its Board of Directors

Canada NewsWire June 22, 2023

HLS Therapeutics Reports Annual Meeting Results

Canada NewsWire June 16, 2023

HLS Therapeutics Announces Agreement with Polar Asset Management Partners and Retirement of Two Directors from the Board of Directors

Canada NewsWire June 8, 2023

HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results

Canada NewsWire May 11, 2023

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call

Canada NewsWire May 3, 2023

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

Canada NewsWire April 21, 2023

HLS Therapeutics Announces CEO Transition

Canada NewsWire April 17, 2023